SMMT — Summit Therapeutics Inc. Common Stock price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $10.67
- YTD price return
- -38.99%
- YTD total return
- -38.99%
- Market cap
- 8.5B
- Enterprise value
- 7.9B
- Shares outstanding
- 799.8M
- 52W low
- $10.53
- 52W high
- $29.23
- From 52W high
- -63.50%
- From 52W low
- +1.33%
- 52W range
- 1%$10.53–$29.23
- Beta
- -1.23
Volume
- Rel volume
- 2.19×
- 30D volume
- 6M
- 30D $ vol
- 90.1M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- none
- Insider net 1Y
- +$103.6M
Form 4 transactions by trade date, as filed; latest on file 2026-06-12.
Fundamentals
- EPS (ttm)
- -$1.07
- FCF (ttm)
- -526.9M
- FCF/share
- -$0.66
- Book value/share
- $0.71
- ROE
- -147.46%
- ROA
- -120.18%
- Current ratio
- 5.99
Growth (CAGR, ttm) · 10Y
- Shares
- +7.44%+4.50%+52.27%+30.40%
Per-share growth (CAGR, ttm) · 10Y
- Book value/share
- +173.58%+70.74%-7.58%n/a
- Price
- -37.07%+76.80%+14.55%-0.35%
- Total return
- -37.07%+76.80%+14.55%-0.35%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -10.0×
- Fwd P/E
- -13.7×
- P/B (mrq)
- 15.1×
- FCF yield (ttm)
- -6.17%
- Buyback yield (realized, 1y)
- -7.44%
- Shareholder yield (realized, 1y)
- -7.44%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/S
- 98th
- P/B
- 60th
Bar = where today’s multiple sits in SMMT’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m5Y n/mYoY n/mEPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y n/m10Y n/mYoY n/mTTM: operating cash flow −$525.2M, capex −$1.7M
Q3 2026: operating cash flow −$159.8M, capex −$396K
Shares (diluted)
5Y +975.5%5Y +975.5%YoY +7.4%Net income
5Y n/m10Y n/mYoY n/mAbout Summit Therapeutics#
Data provided bySource: Twelve DataSummit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs. Summit Therapeutics Inc. centers its current portfolio on oncology, with ivonescimab as its lead investigational asset, a bispecific antibody designed to combine immune checkpoint blockade with anti-angiogenic activity. The company is advancing ivonescimab in multiple late-stage clinical programs for non-small cell lung cancer and colorectal cancer, often in combination with chemotherapy. Summit Therapeutics Inc. also maintains an anti-infectives program, including ridinilazole, an oral antibiotic candidate studied for Clostridioides difficile infection. Through these product and development efforts, Summit Therapeutics Inc. plays a role in precision medicine across cancer and infectious disease, with a focus on therapies intended to address difficult-to-treat conditions.
Miami, FL·265 employees·Biotechnology·smmttx.com·As of Oct 28, 2026
Recent filings#
- Nov 4Earnings · Earnings release — EPS −$0.26 vs −$0.28 est. (+7.1%) 12.2%
- Sep 298-K · AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
- Jul 23Earnings · Earnings release — EPS −$0.28 vs −$0.26 est. (−7.7%) 8.8%
ETFs holding SMMT#
20 of the 193 ETFs ChartRow carries live hold SMMT. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| XBI | SPDR S&P Biotech ETF | 1.0% |
| IBB | iShares Biotechnology ETF | 0.2% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.1% |
| VBR | Vanguard Small-Cap Value ETF | 0.0% |
| VXF | Vanguard Extended Market ETF | 0.0% |
| VHT | Vanguard Health Care ETF | 0.0% |
| ONEQ | Fidelity Nasdaq Composite Index ETF | 0.0% |
| VB | Vanguard Small-Cap ETF | 0.0% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
